Orchard Therapeutics plc
ORTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $6,986 | $483 | $2,595 | $2,513 |
| % Growth | 1,346.4% | -81.4% | 3.3% | – |
| Cost of Goods Sold | $2,433 | $226 | $857 | $805 |
| Gross Profit | $4,553 | $257 | $1,738 | $1,708 |
| % Margin | 65.2% | 53.2% | 67% | 68% |
| R&D Expenses | $25,545 | $23,346 | $93,730 | $117,363 |
| G&A Expenses | $44,657 | $49,646 | $56,893 | $49,158 |
| SG&A Expenses | $10,600 | $13,552 | $64,986 | $57,218 |
| Sales & Mktg Exp. | $4,135 | $5,259 | $8,093 | $8,060 |
| Other Operating Expenses | $0 | $0 | $0 | $1,387 |
| Operating Expenses | $36,145 | $36,898 | $158,716 | $174,581 |
| Operating Income | -$31,592 | -$36,415 | -$156,978 | -$172,873 |
| % Margin | -452.2% | -7,539.3% | -6,049.2% | -6,879.1% |
| Other Income/Exp. Net | -$25,946 | -$3,323 | $4,268 | $7,211 |
| Pre-Tax Income | -$9,012 | -$36,224 | -$152,710 | -$165,662 |
| Tax Expense | -$1,129 | $125 | -$731 | -$2,240 |
| Net Income | -$7,883 | -$36,349 | -$151,979 | -$163,422 |
| % Margin | -112.8% | -7,525.7% | -5,856.6% | -6,503.1% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 |
| % Growth | 79.2% | 80.8% | 12.8% | – |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 |
| Weighted Avg Shares Out | 12,798 | 12,396 | 9,945 | 9,324 |
| Weighted Avg Shares Out Dil | 12,821 | 12,396 | 9,945 | 9,324 |
| Supplemental Information | – | – | – | – |
| Interest Income | $857 | $63 | $3,185 | $7,362 |
| Interest Expense | $933 | $683 | $2,328 | $1,538 |
| Depreciation & Amortization | $23,513 | $874 | $8,600 | $8,749 |
| EBITDA | -$8,079 | -$35,541 | -$148,378 | -$155,375 |
| % Margin | -115.6% | -7,358.4% | -5,717.8% | -6,182.8% |